Actions of immunosuppressor drugs on the development of an experimental ovarian tumor
Immunosuppression has been related to the incidence of tumor apparition, including endocrine tumors. The intrasplenic ovarian tumor (luteoma) is a typical benign endocrine tumor that develops under high gonadotropin stimulation and, from the immunological perspective, is located in a critical organ...
Guardado en:
| Autor principal: | |
|---|---|
| Otros Autores: | , , , |
| Formato: | Capítulo de libro |
| Lenguaje: | Inglés |
| Publicado: |
2002
|
| Materias: | |
| Acceso en línea: | Registro en Scopus Handle Registro en la Biblioteca Digital |
| Aporte de: | Registro referencial: Solicitar el recurso aquí |
| LEADER | 14366caa a22014537a 4500 | ||
|---|---|---|---|
| 001 | PAPER-20305 | ||
| 003 | AR-BaUEN | ||
| 005 | 20230518205142.0 | ||
| 008 | 190411s2002 xx ||||fo|||| 00| 0 eng|d | ||
| 024 | 7 | |2 scopus |a 2-s2.0-0036733357 | |
| 024 | 7 | |2 cas |a Cyclosporine, 59865-13-3; Dexamethasone, 50-02-2; Estradiol, 50-28-2; Follicle Stimulating Hormone, 9002-68-0; Immunosuppressive Agents; Luteinizing Hormone, 9002-67-9; Prolactin, 9002-62-4 | |
| 040 | |a Scopus |b spa |c AR-BaUEN |d AR-BaUEN | ||
| 030 | |a EBMMB | ||
| 100 | 1 | |a Sorianello, E. | |
| 245 | 1 | 0 | |a Actions of immunosuppressor drugs on the development of an experimental ovarian tumor |
| 260 | |c 2002 | ||
| 270 | 1 | 0 | |m Libertun, C.; Inst. de Biol./Medicina Experimental, V. de Obligado 2490, (1428) Buenos Aires, Argentina; email: libertun@dna.uba.ar |
| 506 | |2 openaire |e Política editorial | ||
| 504 | |a Beverley, P., Immunology of cancer (1997) Introduction to the Cellular and Molecular Biology of Cancer, pp. 311-329. , Franks LM, Teich NM, Eds. New York: Oxford University Press | ||
| 504 | |a Sheil, A.G.R., Development of malignancy following renal transplantation in Australia and New Zealand (1992) Transplantation Proc, 24, pp. 1275-1279 | ||
| 504 | |a Biskind, M., Biskind, G., Development of tumors in the rat ovary after transplantation into the spleen (1944) Proc Soc ExpBiol Med, 55, pp. 176-179 | ||
| 504 | |a Lux, V.A.R., Tesone, M., Larrea, G.A., Libertun, C., High correlation between prolactinemia, 125-I hLH binding and progesterone secretion by an experimental luteoma (1984) Life Sci, 35, pp. 2345-2352 | ||
| 504 | |a Lux-Lantos, V.A.R., Thyssen, S.M., Chamson-Reig, A., Libertun, C., Effect of a gonadotropin releasing hormone analog on an experimental ovarian tumor: Direct and indirect actions (1995) Life Sci, 57, pp. 291-300 | ||
| 504 | |a Chamson-Reig, A., Lux-Lantos, V.A.R., Tesone, M., Libertun, C., GnRH receptors and GnRH endocrine effects on luteoma cells (1997) Endocrine, 6, pp. 165-171 | ||
| 504 | |a Chamson-Reig, A., Bianchi, M.S., Rey-Roldán, E.B., Sorianello, E., Libertun, C., Lux-Lantos, V.A., Development of an experimental ovarian tumor over a year in the rat (1999) Life Sci, 65, pp. 1275-1285 | ||
| 504 | |a Hockl, P., Sorianello, E., Chamson-Reig, A., Campo, S., Groome, N., Libertun, C., Lux-Lantos, V., Inhibins and FSH in the early development of an experimental ovarian tumor (2000) International workshop on inhibins, activins, follistatins, p. 60. , Monash Medical Center, Melbourne, Australia. Abstract book | ||
| 504 | |a Chamson-Reig, A., Pignataro, O.P., Libertun, C., Lux-Lantos, V., Alterations in intracellular messengers mobilized by gonadotropin-releasing hormone in an experimental ovarian tumor (1999) Endocrinology, 148, pp. 3573-3580 | ||
| 504 | |a Clark, R.G., Holder, A.T., Ovarian-splenic autotransplantation: Evidence that oestrogen does not inhibit hepatic somatomedin generation (1984) J Endocrinol, 103, pp. 43-47 | ||
| 504 | |a Vom Saal, F.S., Finch, C.E., Reproductive senescence: Phenomena and mechanisms in mammals and selected vertebrates (1986) The Physiology of Reproduction, pp. 2351-2413. , Knobil E, Neill JD, Eds. New York: Raven Press | ||
| 504 | |a Waterhouse, J., (1976) Cancer Incidence in Five Continents, p. 15. , Lyons, France: IARC Scientific Publications | ||
| 504 | |a Rao, R.B., Slotman, B., Endocrine factors in common epithelial ovarian cancer (1991) Endocrine Rev, 12, pp. 14-26 | ||
| 504 | |a Willemsen, W., Kruitwagen, R., Bastiaans, B., Hanselaar, T., Rolland, R., Ovarian stimulation and granulosa-cell tumour (1993) Lancet, 341, pp. 986-988 | ||
| 504 | |a Yen, S.S.C., The polycystic ovary syndrome (1980) Clin Endocrinol, 12, pp. 177-208 | ||
| 504 | |a MacLeod, A.F., Wleeler, M.J., Gordon, C., Lowy, C., Sonksen, P.H., Conaglen, J.V., Effect of long-term inhibition of gonadotrophin secretion by the gonadotrophin-releasing hormone agonist, buserelin, on sex steroid secretion and ovarian morphology in polycystic ovary syndrome (1989) J Endocrinol, 125, pp. 317-325 | ||
| 504 | |a Zinkernagel, R.M., Ehl, S., Aichele, P., Oehen, S., Kündig, T., Hengartner, H., Antigen localisation regulates immune response in a dose- and time-dependent fashion: A geographical view of immune reactivity (1997) Immunol Rev, 156, p. 209 | ||
| 504 | |a Sigal, N.H., Dumont, F.J., Cyclosporin, A., FK-506, and rapamycin: Pharmacologic probes of lymphocyte signal transduction (1992) Annu Rev Immunol, 10, pp. 519-560 | ||
| 504 | |a Arai, S., Vogelsang, G.B., Management of graft-versus-host disease (2000) Blood Rev, 14, pp. 190-204 | ||
| 504 | |a Fauci, A.S., Dale, D.C., Balow, J.E., Glucocorticosteroid therapy: Mechanisms of action and clinical considerations (1976) Ann Intern Med, 84, pp. 304-315 | ||
| 504 | |a De Bosscher, K., Shmitz, M.L., Vanden Berghe, W., Plaisance, S., Fiers, W., Haegeman, G., Glucocorticoid-mediated repression of nuclear factorκB-dependent transcription involves direct interference with transactivation (1997) Proc Natl Acad Sci U S A, 94, pp. 13504-13509 | ||
| 504 | |a Rondinone, C.M., Schillaci, R., Castillo, M.B., Roldán, A., Inhibitory Effect of 11-hydroxypregna-1,4-diene-3,20-dione (A HOP) on lymphocyte proliferation (1991) Clin Expt Immun, 86, pp. 311-314 | ||
| 504 | |a Ashwell, J.D., Lu, F.W.M., Vacchio, M.S., Glucocorticoids in T cell development and function (2000) Annu Rev Immunol, 18, pp. 309-345 | ||
| 504 | |a Rondinone, C.M., Schillaci, R., Lantos, C.P., Roldán, A., Appearance and persistence of 11-hydroxypregna-1,4-diene-3,20-dione (ΔHOP) effect 'in vivo' (1989) Acta Physiol Pharmacol Latinoamer, 39, p. 181 | ||
| 504 | |a Murphy, P., Alexander, P., Senior, P.V., Fleming, J., Kirkham, N., Taylor, I., Mechanisms of organ selective tumour growth by bloodborne cancer cells (1988) Br J Cancer, 57, pp. 19-31 | ||
| 504 | |a Hojo, M., Morimoto, T., Maluccio, M., Asano, T., Morimoto, K., Lagman, M., Shimbo, T., Suthanthiran, M., Cyclosporine induces cancer progression by a cell-autonomous mechanism (1999) Nature, 397, pp. 530-534 | ||
| 504 | |a DeSombre, E.R., Arbogast, L.Y., Effect of the antiestrogen CI 628 on the growth of rat mammary tumors (1974) Cancer Res, 34, pp. 1971-1974 | ||
| 504 | |a Sokal, R.R., Rohlf, F.J., (1995) Biometry, , New York: W.H. Freeman and Co | ||
| 504 | |a Lison, L., (1976) Datos enumerativos. Comparación de proporciones. Estadística aplicada a la biología experimental, pp. 307-327. , Buenos Aires: Editorial Universitaria de Buenos Aires | ||
| 504 | |a Sorianello, E., Fritz, S., Beyer, C., Hales, D., Mayerhofer, A., Libertun, C., Lux-Lantos, V., Development of an experimental ovarian tumor: Immunocytochemical analysis Eur J Endocrinol, , In Press | ||
| 504 | |a Coirini, H., Flores, D., Vega, M.C., Gonzalez Deniselle, M.C., De Nicola, A.F., Binding of the anti-inflammatory steroid deflazacort to glucocorticoid receptors in brain and peripheral tissues: In vivo and in vitro studies (1994) J Steroid Biochem Mol Biol, 49, pp. 43-49 | ||
| 504 | |a Whiting, P.H., Simpson, J.G., Davidson, R.J.L., Thomson, A.W., Pathological changes in rats receiving cyclosporin A at immunotherapeutic dosage for 7 weeks (1983) Br J Exp Pathol, 64, pp. 437-444 | ||
| 504 | |a Damoiseaux, J.G.M.C., Beijleveld, L.J.J., Van Breda Vriesman, P.J.C., (1997) Clin Immunol Immunopathol, 82, pp. 197-202 | ||
| 504 | |a Hedger, M.P., Drummond, A.E., Robertson, D.M., Risbridger, G.P., De Kretset, D.M., Inhibin and activin regulate [3H]thymidine uptake by rat thymocytes and 3T3 cells in vitro (1989) Mol Cell Endocrinol, 61, pp. 133-138 | ||
| 504 | |a Sabharwal, P., Varma, S., Growth hormone synthesized and secreted by human thymocytes acts via insulin-like growth factor I as an autocrine and paracrine growth factor (1996) J Clin Endocrinol Metab, 81, pp. 2663-2669 | ||
| 504 | |a Beschorner, W.E., Divic, J., Pulido, H., Yao, X., Kenworthy, P., Bruce, G., Enhancement of thymic recovery after cyclosporine by recombinant human growth hormone and insulin-like growth factor I (1991) Transplantation, 52, pp. 879-884 | ||
| 504 | |a Esquifino, A.I., Moreno, M.L., Agrasal, C., Villanúa, M.A., Effects of cyclosporine on ovarian function in sham-operated and pituitary-grafted young female rats (1995) Proc Soc Exp Biol Med, 208, pp. 397-403 | ||
| 504 | |a Pellegrini, I., Lebrun, J.-J., Ali, S., Kelly, P.A., Expression of prolactin and its receptor in human lymphoid cells (1992) Mol Endocrinol, 6, pp. 1023-1031 | ||
| 504 | |a Russell, D.H., Matrisian, L., Kibler, R., Larson, D.F., Poulos, B., Magun, B.E., Prolactin receptors on human lymphocytes and their modulation by cyclosporine (1984) Biochem Biophys Res Commun, 121, pp. 899-906 | ||
| 504 | |a Woody, M.A., Welniak, L.A., Sun, R., Tian, Z.G., Henry, M., Richards, S., Raziuddin, A., Murphy, W.J., Prolactin exerts hematopoietic growth-promoting effects in vivo and partially counteracts myelosuppression by azidothymidine (1999) Exp Hematol, 27, pp. 811-816 | ||
| 504 | |a Van Nierkerk, C.C., Ramaekers, F.C., Hanselaar, A.G., Alderweireldt, J., Poels, L.G., Changes in expression of differentiation markers between normal ovarian cells and derived tumors (1993) Am J Pathol, 142, pp. 157-177 | ||
| 504 | |a Ochsenbein, A.F., Sierro, S., Odermatt, B., Pericin, M., Karrer, U., Hermans, J., Hemmi, S., Zinkernagel, R.M., Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction (2001) Nature, 411, pp. 1058-1064 | ||
| 520 | 3 | |a Immunosuppression has been related to the incidence of tumor apparition, including endocrine tumors. The intrasplenic ovarian tumor (luteoma) is a typical benign endocrine tumor that develops under high gonadotropin stimulation and, from the immunological perspective, is located in a critical organ involved in immune response. To establish if immunosuppression could alter the development of this experimental tumor, the effects of cyclosporin A (CsA) and dexamethasone (Dex) were evaluated. After surgery, tumor-bearing and sham animals were kept without treatment for 4 weeks; thereafter, they were distributed into CsA (25 mg/kg), Dex (0.1 mg/kg), or vehicle (75:25 castor oil:ethanol) groups and were injected on alternate days for 50 days. Body weight was evaluated weekly. Animals were sacrificed after a jugular vein blood sample was obtained. Thyml were weighed. Tumors were measured and placed in formaline for histological studies. Serum luteinizing hormone (LH), follicle-stimulating hormone (FSH), prolactin (PRL), and estradiol were measured by radioimmunoassay. Hematological parameters were determined. CsA induced a significant decrease in survival rates both in tumor-bearing and sham animals (P < 0.01). Dex significantly impaired weight increase in both groups of animals. CsA induced a significant weight loss in sham animals, not observed in tumor-bearing animals. Dex induced thymus weight loss in both groups, whereas CsA induced thymus weight loss only in sham animals. Only Dex induced a decrease in lymphocyte number in both groups. CsA induced an increase in monocyte number only in sham animals. Treatments did not alter LH, FSH, or estradiol, whereas PRL was increased by CsA only in sham rats. Neither Dex nor CsA induced any significant variations in tumor volume, nor did they alter tumor histology. In addition, no visible metastases or alterations in other organs were observed. We conclude that, though immunological parameters were altered by the treatments, immunosuppressor drugs did not condition tumor development. In addition, tumors secrete one or more factor/s that counteract CsA effect. |l eng | |
| 593 | |a Inst. de Biol. y Med. Exp.-Consejo Nacional de Investigaciones Cientificas y Tecnicas, Facultad de Medicina, Universidad de Buenos Aires, (1428) Buenos Aires, Argentina | ||
| 593 | |a Departmento de Fisiología, Facultad de Medicina, Universidad de Buenos Aires, Vuelta de Obligado 2490, (1428) Buenos Aires, Argentina | ||
| 690 | 1 | 0 | |a CYCLOSPORIN A |
| 690 | 1 | 0 | |a DEXAMETHASONE |
| 690 | 1 | 0 | |a IMMUNOSUPPRESSION |
| 690 | 1 | 0 | |a LUTEOMA |
| 690 | 1 | 0 | |a CYCLOSPORIN A |
| 690 | 1 | 0 | |a DEXAMETHASONE |
| 690 | 1 | 0 | |a ESTRADIOL |
| 690 | 1 | 0 | |a FOLLITROPIN |
| 690 | 1 | 0 | |a IMMUNOSUPPRESSIVE AGENT |
| 690 | 1 | 0 | |a LUTEINIZING HORMONE |
| 690 | 1 | 0 | |a PROLACTIN |
| 690 | 1 | 0 | |a ANIMAL EXPERIMENT |
| 690 | 1 | 0 | |a ANIMAL MODEL |
| 690 | 1 | 0 | |a ANIMAL TISSUE |
| 690 | 1 | 0 | |a ARTICLE |
| 690 | 1 | 0 | |a CANCER GROWTH |
| 690 | 1 | 0 | |a CANCER RISK |
| 690 | 1 | 0 | |a CHEMICAL CARCINOGENESIS |
| 690 | 1 | 0 | |a CONTROLLED STUDY |
| 690 | 1 | 0 | |a EXPERIMENTAL NEOPLASM |
| 690 | 1 | 0 | |a FEMALE |
| 690 | 1 | 0 | |a HISTOPATHOLOGY |
| 690 | 1 | 0 | |a IMMUNOSUPPRESSIVE TREATMENT |
| 690 | 1 | 0 | |a LUTEOMA |
| 690 | 1 | 0 | |a MOUSE |
| 690 | 1 | 0 | |a NONHUMAN |
| 690 | 1 | 0 | |a ANIMALS |
| 690 | 1 | 0 | |a BODY WEIGHT |
| 690 | 1 | 0 | |a CYCLOSPORINE |
| 690 | 1 | 0 | |a DEXAMETHASONE |
| 690 | 1 | 0 | |a ESTRADIOL |
| 690 | 1 | 0 | |a FEMALE |
| 690 | 1 | 0 | |a FOLLICLE STIMULATING HORMONE |
| 690 | 1 | 0 | |a IMMUNOCOMPROMISED HOST |
| 690 | 1 | 0 | |a IMMUNOSUPPRESSIVE AGENTS |
| 690 | 1 | 0 | |a LUTEINIZING HORMONE |
| 690 | 1 | 0 | |a LUTEOMA |
| 690 | 1 | 0 | |a NEOPLASM TRANSPLANTATION |
| 690 | 1 | 0 | |a ORGAN SIZE |
| 690 | 1 | 0 | |a OVARIAN NEOPLASMS |
| 690 | 1 | 0 | |a OVARIECTOMY |
| 690 | 1 | 0 | |a OVARY |
| 690 | 1 | 0 | |a PROLACTIN |
| 690 | 1 | 0 | |a RATS |
| 690 | 1 | 0 | |a RATS, SPRAGUE-DAWLEY |
| 690 | 1 | 0 | |a SPLEEN |
| 690 | 1 | 0 | |a THYMUS GLAND |
| 690 | 1 | 0 | |a TRANSPLANTATION, HETEROTOPIC |
| 690 | 1 | 0 | |a ANIMALIA |
| 690 | 1 | 0 | |a CASTOR |
| 653 | 0 | 0 | |a sandimmun neoral, Sandoz, Argentina |
| 700 | 1 | |a Schillaci, R. | |
| 700 | 1 | |a Chamson-Reig, A. | |
| 700 | 1 | |a Lux-Lantos, V. | |
| 700 | 1 | |a Libertun, C. | |
| 773 | 0 | |d 2002 |g v. 227 |h pp. 658-664 |k n. 8 |p Exp. Biol. Med. |x 00379727 |w (AR-BaUEN)CENRE-2685 |t Experimental Biology and Medicine | |
| 856 | 4 | 1 | |u https://www.scopus.com/inward/record.uri?eid=2-s2.0-0036733357&partnerID=40&md5=8187a6b9542a3799e82d1ef05d6254de |y Registro en Scopus |
| 856 | 4 | 0 | |u https://hdl.handle.net/20.500.12110/paper_00379727_v227_n8_p658_Sorianello |y Handle |
| 856 | 4 | 0 | |u https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_00379727_v227_n8_p658_Sorianello |y Registro en la Biblioteca Digital |
| 961 | |a paper_00379727_v227_n8_p658_Sorianello |b paper |c PE | ||
| 962 | |a info:eu-repo/semantics/article |a info:ar-repo/semantics/artículo |b info:eu-repo/semantics/publishedVersion | ||